INT48728

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 28
Total Number 28
Disease Relevance 14.84
Pain Relevance 1.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IGFBP3) extracellular region (IGFBP3) nucleus (IGFBP3)
Anatomy Link Frequency
plasma 3
neurons 2
colon 1
fibroblasts 1
band 1
IGFBP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 1 98.52 Very High Very High Very High
Bioavailability 11 96.48 Very High Very High Very High
Dynorphin 4 95.68 Very High Very High Very High
Clonidine 7 93.48 High High
metalloproteinase 27 91.04 High High
rheumatoid arthritis 154 78.40 Quite High
endometriosis 3 75.00 Quite High
Neuropeptide 12 71.36 Quite High
anesthesia 20 65.64 Quite High
Somatostatin 1 44.08 Quite Low
Disease Link Frequency Relevance Heat
Targeted Disruption 172 99.96 Very High Very High Very High
Apoptosis 124 99.72 Very High Very High Very High
Adhesions 254 99.68 Very High Very High Very High
Sleep Disorders 276 99.60 Very High Very High Very High
Thyroid Disease 28 99.36 Very High Very High Very High
Colon Cancer 38 99.24 Very High Very High Very High
Cancer 491 98.86 Very High Very High Very High
Diabetes Mellitus 25 98.32 Very High Very High Very High
Growth Problems 17 96.76 Very High Very High Very High
Adenoma 47 95.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Epidemiological studies support an association between elevated circulating levels of IGF-I and reduced IGFBP-3 levels in the circulation and increased risk of breast [20,21], prostate [22], and colorectal cancer or adenoma [23-26].
Negative_regulation (reduced) of IGFBP-3 associated with adenoma and colon cancer
1) Confidence 0.59 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 0.93 Pain Relevance 0.04
Western immunoblotting of column effluent with IGFBP-3 antiserum revealed immunoreactive IGFBP-3 forms of 37-43 kDa (major) and 28 kDa (minor) in serum and almost exclusively the 28-kDa band in PF, suggesting that IGFBP-3 in PF may be proteolytically processed.
Negative_regulation (revealed) of IGFBP-3 in band
2) Confidence 0.40 Published 1994 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 7525631 Disease Relevance 0.07 Pain Relevance 0.04
In this study we examine genetic, anthropometric, diet, and lifestyle factors that may predict serum levels of IGF-I and IGFBP-3 among Hispanic and non-Hispanic white women.
Negative_regulation (predict) of IGFBP-3
3) Confidence 0.40 Published 2005 Journal Cancer Causes Control Section Abstract Doc Link 16215864 Disease Relevance 0.33 Pain Relevance 0
They had significantly decreased circulating concentrations of IGF-I and IGFBP-3 (47.5 +/- 19 ng/ml and 1.2 +/- 0.27 mg/l respectively) compared with those with CSS (153 +/- 42 ng/ml and 2.06 +/- 0.37 mg/l respectively), but the IGF-I and IGFBP-3 concentrations were not different from those with GHD (56 +/- 25 ng/ml and 1.1 +/- 0.32 mg/l respectively).
Negative_regulation (decreased) of IGFBP-3 associated with growth problems
4) Confidence 0.40 Published 1998 Journal Eur. J. Endocrinol. Section Abstract Doc Link 9578506 Disease Relevance 0.68 Pain Relevance 0.17
These data demonstrate that the GH-IGF-I-IGFBP-3 axis in thalassaemic children is defective.
Negative_regulation (defective) of IGFBP-3
5) Confidence 0.40 Published 1998 Journal Eur. J. Endocrinol. Section Abstract Doc Link 9578506 Disease Relevance 0.65 Pain Relevance 0.14
Decrease in the levels of IGFBP-3 in the adhesion fibroblasts may promote adhesion development both by increasing proliferation and reducing apoptosis at the site of injury.
Negative_regulation (Decrease) of IGFBP-3 in fibroblasts associated with injury, apoptosis and adhesions
6) Confidence 0.39 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC548295 Disease Relevance 1.36 Pain Relevance 0
Reduced levels of IGFBP3 mRNA are reported in the tumorigenic cells [38].
Negative_regulation (Reduced) of IGFBP3 mRNA
7) Confidence 0.39 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC548295 Disease Relevance 1.19 Pain Relevance 0
Other transcripts were also found (Table 3), only one of which, IGFBP3, was downregulated in human narcolepsy hypothalami.
Negative_regulation (downregulated) of IGFBP3 associated with sleep disorders
8) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2617764 Disease Relevance 0.50 Pain Relevance 0.05
Among many additional candidates, only one, insulin-like growth factor binding protein 3 (IGFBP3), was downregulated in both human and mouse models and co-expressed in hypocretin neurons.
Negative_regulation (downregulated) of insulin-like growth factor binding protein 3 in neurons
9) Confidence 0.37 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2617764 Disease Relevance 0.63 Pain Relevance 0.04
Among many additional candidates, only one, insulin-like growth factor binding protein 3 (IGFBP3), was downregulated in both human and mouse models and co-expressed in hypocretin neurons.
Negative_regulation (downregulated) of IGFBP3 in neurons
10) Confidence 0.27 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2617764 Disease Relevance 0.62 Pain Relevance 0.03
In 2003, Iglesias et al. [26] stated that hypothyroidism is associated with significant reductions of IGF-1 and IGFBP-3.
Negative_regulation (reductions) of IGFBP-3 associated with thyroid disease
11) Confidence 0.24 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.58 Pain Relevance 0
Hypocretin-1 peptide contents were significantly decreased primarily in hIGFBP3 transgenic and less so in humtIGFBP3 transgenic mice compared to controls, indicating both IGF dependent and less prominently independent properties of IGFBP3 affect hypocretin production (Fig 3B).
Negative_regulation (decreased) of hIGFBP3 associated with targeted disruption
12) Confidence 0.24 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2617764 Disease Relevance 1.42 Pain Relevance 0
IGFBP-3 stabilizes circulating IGF-I, and reductions in IGFBP-3 can contribute to a decrease in IGF-I levels (due to decreased stability of the complex).
Negative_regulation (reductions) of IGFBP-3
13) Confidence 0.19 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206381 Disease Relevance 0.53 Pain Relevance 0.13
IGFBP-3 decreased by 0.8 mg/liter (24%, P < 0.01) and 2.9 mg/liter (37%, P < 0.005), respectively.
Negative_regulation (decreased) of IGFBP-3
14) Confidence 0.17 Published 2006 Journal J. Clin. Endocrinol. Metab. Section Body Doc Link 16720661 Disease Relevance 0.07 Pain Relevance 0
Secondary outcome measures were reduction in serum IGF binding protein-3 (IGFBP-3), improvement of fatigue and sweating, and reduction in markers of bone metabolism and bone pain.
Negative_regulation (reduction) of IGF binding protein-3
15) Confidence 0.17 Published 2006 Journal J. Clin. Endocrinol. Metab. Section Body Doc Link 16720661 Disease Relevance 0.08 Pain Relevance 0
CONCLUSIONS: Pegvisomant effectively reduced IGF-I and IGFBP-3 levels in gsp-mediated GH excess but had no effect on fibrous dysplasia.


Negative_regulation (reduced) of IGFBP-3
16) Confidence 0.17 Published 2006 Journal J. Clin. Endocrinol. Metab. Section Body Doc Link 16720661 Disease Relevance 0 Pain Relevance 0
Secondary outcome measures were reduction in serum IGF binding protein-3 (IGFBP-3), improvement of fatigue and sweating, and reduction in markers of bone metabolism and bone pain.
Negative_regulation (reduction) of IGFBP-3
17) Confidence 0.17 Published 2006 Journal J. Clin. Endocrinol. Metab. Section Body Doc Link 16720661 Disease Relevance 0.08 Pain Relevance 0
GH receptor antagonist treatment decreased colon carcinoma growth in nude mice, associated with reduction in circulating IGFBP3 levels [33].
Negative_regulation (reduction) of IGFBP3 in colon associated with antagonist and colon cancer
18) Confidence 0.15 Published 2006 Journal BMC Genomics Section Body Doc Link PMC1774576 Disease Relevance 1.14 Pain Relevance 0.05
Reduced serum concentrations of IGFBP-3 can result from a primary decrease in IGFBP-3 production, or secondarily, due to a reduction in IGF-I.
Negative_regulation (Reduced) of IGFBP-3
19) Confidence 0.14 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206381 Disease Relevance 0.52 Pain Relevance 0.13
The fact that when exogenous IGFBP-3 is added to the postoperative plasma no increase in the in vitro tumor growth rate over baseline is observed suggests that the decrease in IGFBP-3 levels is responsible for the tumor growth stimulation noted with the “raw” postoperative plasma [50].


Negative_regulation (decrease) of IGFBP-3 in plasma associated with cancer
20) Confidence 0.13 Published 2009 Journal Surg Endosc Section Body Doc Link PMC2814196 Disease Relevance 0.80 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox